OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development

University of Washington Professor to Oversee Expanded R&D Operations at Icogenex Bioincubator R&D Facility in Seattle, Washington.

Business Wire

SAN DIEGO--(BUSINESS WIRE)--

OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, has appointed Jean S. Campbell, Ph.D. as Executive Director of Research and Development, a newly created position. Dr. Campbell, an Associate Professor in the Department of Pathology in the School of Medicine at the University of Washington, Seattle, will leverage her considerable expertise in cancer biology and signal transduction to investigate mechanisms of immune tolerance in cancer.

“Dr. Campbell brings to the OncoSec team an extensive research background and a deep understanding of cancer biology and tumor progression,” said Punit Dhillon, President and CEO. “We are thrilled to have her join us at this pivotal moment in OncoSec’s history. Hiring Dr. Campbell and building OncoSec’s internal capabilities for proprietary drug discovery and preclinical development are key steps forward to delivering a differentiated immune-oncology pipeline.”

Robert Pierce, M.D., Chief Medical Officer, said, “Until now, we have exclusively focused on driving our existing clinical trials forward. Given the success of those trials and the largely untapped promise of ImmunoPulse as a platform for delivering immunomodulatory DNA constructs, we feel that now is the right time in OncoSec’s evolution to expand our bevy of drug candidates. Dr. Campbell and her team are well positioned to increase our research and development (R&D) efforts through this critical period, as we look at near-term data from our Phase II programs and advancements of our ImmunoPulse programs and platform.”

Prior to joining OncoSec Medical, Dr. Campbell was liaison for the Northwest Liver Research Program and a principal investigator of an R01-funded research laboratory. She played an active role in developing the graduate curriculum in translational aspects of disease mechanisms and served as course director for multiple courses, mentoring numerous graduate and undergraduate students.

Dr. Campbell completed her post-doctoral training at the University of Washington in Seattle with Dr. Bennett Shapiro, currently a Senior Partner and Chairman of the Board at PureTech Ventures, and the late Dr. Edwin Krebs, recipient of the Nobel Prize in Medicine or Physiology in 1992. She received her Ph.D. from the University Wisconsin in Madison and completed her undergraduate studies in chemistry at The College of Wooster in Ohio.

She is the co-author of more than 70 peer-reviewed journal articles and book chapters, and a reviewer for numerous scientific journals and grant review panels.

Dr. Campbell said, “Immunotherapy holds great promise as a therapeutic modality for oncology and chronic diseases. We now seek to better understand the basic mechanisms of immune modulation within the tumor microenvironment and its capacity to affect systemic anti-tumor immune responses.”

Separately, OncoSec announced the expansion of its R&D capabilities with dedicated laboratory space at the Icogenex Bioincubator in Seattle. OncoSec currently employs six scientists between Seattle and San Diego, and the company is projecting to hire at least 15 new R&D employees over the next year. The laboratory gives OncoSec a temporary but scalable space with access to a state-of-the-art facility with both molecular and cellular biology capabilities.

“We are excited about this expansion of our capacity and bandwidth in R&D,” said Punit Dhillon. “We have built close relationships with some of the most prestigious academic research centers, such as University of Washington and the Fred Hutchinson Cancer Research Center, and this facility will allow us to offer even more direct access to these partners. That, coupled with the robust life sciences cluster in the region, makes Seattle a perfect fit for our business. Now, with screening new targets to pre-clinical development capabilities available in-house, OncoSec will truly be able to expand our R&D pipeline.”

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma (http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search). As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact:
Investor Relations:
OncoSec Medical Inc.
Veronica Vallejo, CFO
855-662-6732
investors@oncosec.com

View Comments (0)